This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Narrowing post #89, because the general version has more than one answer.
Practical experience of Research-use-only status, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.
I would call that likely rather than established.
I would be cautious about generalising from the Research-use-only status example above. It is a good example. It is one example.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The claim is narrower than it sounds, and deliberately so.
Research-use-only status: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Where I part company with post #94, and it is a narrow parting.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Coming back to post #98, because the follow-up matters more than the original answer.
Whatever the answer on Research-use-only status turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The version of Research-use-only status that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Picking up post #102: that is the part I would want checked first.
Agreed on Research-use-only status, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
Posting it because the silence on this was starting to look like agreement.
Adding a reference point for Research-use-only status. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Post #107 answers the question as asked. The question underneath it is different.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
Research-use-only status is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
I would rather this thread reach "we do not know" about Research-use-only status than reach a confident answer that nobody can support when asked.
Post #111 describes the usual case. This is about the unusual one.
I changed my mind about Research-use-only status after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
Adding the measurement that post #111 says would settle it.
Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.
Stating my assumptions rather than smuggling them in.
What would change my mind on Research-use-only status is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I read post #116 twice before replying, because I had assumed the opposite.
Speaking only to Research-use-only status as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Post #119 answers the question as asked. The question underneath it is different.
A request rather than an answer: could whoever has the primary source for Research-use-only status post it? I have seen the claim three times this month and each version had lost a qualifier.